Breast cancer: Tracking ctDNA to evaluate relapse risk

Nature Reviews Clinical Oncology

Volumn 12, Issue 11, 2015, Pages 624-

  Romero, Diana ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULATING TUMOR DNA; DNA; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; DNA DETERMINATION; FOLLOW UP; HUMAN; MINIMAL RESIDUAL DISEASE; NOTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK ASSESSMENT; SOMATIC MUTATION; BREAST TUMOR; FEMALE; GENETICS; MUTATION;

BREAST NEOPLASMS; DNA, NEOPLASM; FEMALE; HUMANS; MUTATION;

EID: 84946475517     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.159     Document Type: Note

References (1)

1. Original article Prost, S. et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists. Nature doi:10.1038/nature15248